Literature DB >> 24727397

Outcome of endovascular treatment in postthrombotic syndrome.

Hongfei Sang1, Xiaoqiang Li2, Aimin Qian1, Qingyou Meng1.   

Abstract

BACKGROUND: The postthrombotic syndrome (PTS) is a chronic complication of deep venous thrombosis (DVT) that is characterized by leg swelling and ulceration.
METHODS: Sixty-seven cases of PTS underwent attempted endovascular treatment with success in 63 between June 2005 and June 2012. Thirty-six cases underwent endovascular treatment only and 18 cases combined with temporary femoral arteriovenous fistula, 5 cases great saphenous vein ligation and stripping whereas 4 cases with communicating branch ligation around ulcers.
RESULTS: Stenting was successfully performed in 63 of 67 patients. The technical success rate was 94% with no mortality. Fifty-eight cases were followed up from 1 to 84 months. Stent occlusion or restenosis occurred in 17 patients. The primary and secondary patency rates were 87.9% and 93.1%, respectively, at 12 months and 70.7% and 82.8%, respectively, at 36 months.
CONCLUSIONS: Endovascular treatment of PTS is safe and effective. It can alleviate symptoms and prevent further deterioration of patients with PTS.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24727397     DOI: 10.1016/j.avsg.2014.03.031

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  7 in total

1.  Long-term follow-up of the stenting across the iliocaval confluence in patients with iliac venous lesions.

Authors:  Xicheng Zhang; Yuanhu Jing; Hongfei Sang; Zhaolei Chen; Yuan Sun; Xiaoqiang Li
Journal:  J Thromb Thrombolysis       Date:  2019-01       Impact factor: 2.300

2.  Short- and Mid-Term Outcomes of Endovascular Stenting for the Treatment of Post-Thrombotic Syndrome due to Iliofemoral and Caval Occlusive Disease: A Multi-Centric Study from the French Society of Diagnostic and Interventional Cardiovascular Imaging (SFICV).

Authors:  Arthur David; Frédéric Thony; Costantino Del Giudice; Gilles Goyault; Romaric Loffroy; Kévin Guillen; Yann Le Bras; Clément Marcelin; Valérie Monnin-Bares; Jean-François Heautot; Alexandre Lablee; Pierre Marek; Hervé Rousseau; Thomas Martinelli; Francine Thouveny; Pierre-Antoine Barral; Vincent Le Pennec; Pascal Chabrot; André Rogopoulos; Alicia Guillien; Marc Sapoval; Matthieu Rodière; Olivier Espitia; Frédéric Douane
Journal:  Cardiovasc Intervent Radiol       Date:  2022-01-04       Impact factor: 2.740

3.  Three-Year Results from the Venovo Venous Stent Study for the Treatment of Iliac and Femoral Vein Obstruction.

Authors:  Michael D Dake; Gerard O'Sullivan; Nicolas W Shammas; Michael Lichtenberg; Bibombe P Mwipatayi; Richard A Settlage
Journal:  Cardiovasc Intervent Radiol       Date:  2021-09-20       Impact factor: 2.740

4.  A Systematic Review and Meta-Analysis of 12-Month Patency After Intervention for Iliofemoral Obstruction Using Dedicated or Non-Dedicated Venous Stents.

Authors:  Ghulam M Majeed; Krishan Lodhia; Jemima Carter; Jack Kingdon; Rachael I Morris; Adam Gwozdz; Athanasios Saratzis; Prakash Saha
Journal:  J Endovasc Ther       Date:  2021-11-10       Impact factor: 3.089

5.  Excellent long-term results with iliac stenting in local anesthesia for post-thrombotic syndrome.

Authors:  Lotte Klitfod; Sven Just; Pia Foegh; Niels Baekgaard
Journal:  Acta Radiol Open       Date:  2015-09-11

6.  Postinterventional antithrombotic management after venous stenting of the iliofemoral tract in acute and chronic thrombosis: A systematic review.

Authors:  Pascale Notten; Hugo Ten Cate; Arina J Ten Cate-Hoek
Journal:  J Thromb Haemost       Date:  2021-01-05       Impact factor: 5.824

7.  Pivotal Study Evaluating the Safety and Effectiveness of the Abre Venous Self-Expanding Stent System in Patients With Symptomatic Iliofemoral Venous Outflow Obstruction.

Authors:  Erin Murphy; Kathleen Gibson; Marc Sapoval; David J Dexter; Raghu Kolluri; Mahmood Razavi; Stephen Black
Journal:  Circ Cardiovasc Interv       Date:  2022-02-02       Impact factor: 6.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.